Adicet Bio Advances Prula-Cel Toward SLE Data Readout
REDWOOD CITY, Calif., September 1, 2026 Adicet Bio announced completion of the last patient visit for the planned Phase...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
REDWOOD CITY, Calif., September 1, 2026 Adicet Bio announced completion of the last patient visit for the planned Phase...
San Diego, California — August 14, 2026 Fate Therapeutics, Inc. has initiated the potentially registrational RECLAIM-LN Phase 2 clinical...
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 Persephoni BioSciences has announced a strategic investment in SelSym Biotech, bringing the...
SOUTH SAN FRANCISCO, Calif., July 14, 2026 Genentech, a member of the Roche Group, has received U.S. Food and...
SAN DIEGO, July 6, 2026 Fate Therapeutics announced that preliminary clinical data from its investigational FT819 off-the-shelf CD19-targeting CAR...
ROCKVILLE, Maryland and EDMONTON, Alberta, July 6, 2026 Aurinia Pharmaceuticals Inc. announced the initiation of PRESERVE, a Phase 4,...
MISSISSAUGA, Ontario, May 22, 2026 Roche Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation...
Miami, Florida – October 30, 2025 — Allosite Therapeutics, a biotechnology company pioneering allosteric integrin agonists for the treatment...
